Adolor Corporation - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Adolor Corporation. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Adolor Corporation. The Group's principal activity is to discover, develop and market proprietary biopharmaceutical products for the treatment of pain and the side effects that are caused by current pain treatments. The Group is in the development stage and has a portfolio of small molecule product candidates that are in various stages of development ranging from pre-clinical studies to advanced stage clinical trials. The Group recently completed Phase 1 clinical testing of ADL5747 and have not observed any dose-limiting toxicity or serious adverse events with this compound. It's most advanced product candidate, Entereg(R) is intended to block the adverse side effects of opioid analgesics on the gastrointestinal tract without affecting analgesia. Entereg(R) has been under development for both acute and chronic conditions. The acute indication is for the management of post operative ileus & the chronic indication is for the treatment of opioid bowel dysfunction.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report